Data gathered: February 1
AI Stock Analysis - Acumen Pharmaceuticals (ABOS)
Analysis generated October 29, 2024. Powered by Chat GPT.
Acumen Pharmaceuticals is a biotechnology firm that focuses on the development and commercialization of therapeutics to address unmet medical needs. The company's strategy involves rigorous scientific and regulatory approaches, emphasizing innovative and evidence-based solutions. Despite the high potential in the biotech sector, companies like Acumen are subject to considerable financial risks and benefits related to their product pipeline, regulatory approvals, and market adoption.
Stock Alerts - Acumen Pharmaceuticals (ABOS)
 |
Acumen Pharmaceuticals | January 24 Price is down by -5.3% in the last 24h. |
|
Acumen Pharmaceuticals | January 24 Insider Alert: Zuga Matt is selling shares |
|
Acumen Pharmaceuticals | January 22 Price is up by 6.8% in the last 24h. |
|
Acumen Pharmaceuticals | January 16 Price is down by -5.3% in the last 24h. |
Alternative Data for Acumen Pharmaceuticals
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 2 | Sign up | Sign up | Sign up |
| Sentiment | 94 | Sign up | Sign up | Sign up |
| Webpage traffic | 3,000 | Sign up | Sign up | Sign up |
| Google Trends | 75 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Facebook Engagement | 2 | Sign up | Sign up | Sign up |
| Facebook Followers | 2,353 | Sign up | Sign up | Sign up |
| Instagram Followers | 115 | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 1,106 | Sign up | Sign up | Sign up |
| Twitter Followers | 256 | Sign up | Sign up | Sign up |
| Twitter Mentions | 35 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Linkedin Employees | 66 | Sign up | Sign up | Sign up |
About Acumen Pharmaceuticals
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease.
| Price | $1.50 |
| Target Price | Sign up |
| Volume | 281,160 |
| Market Cap | $94M |
| Year Range | $1.5 - $3.54 |
| Dividend Yield | 0% |
| Analyst Rating | 100% buy |
| Industry | Biotechnology |
In the news
 |
Cantor Fitzgerald Comments on ABOS FY2025 EarningsJanuary 23 - ETF Daily News |
 |
Acumen Pharmaceuticals CEO O'Connell sells shares worth $20,102January 23 - Investing.com |
 |
Acumen Pharmaceuticals COO Barton Russell sells shares worth $4,692January 23 - Investing.com |
|
Acumen Pharmaceuticals chief legal officer sells shares worth $5,434January 23 - Investing.com |
|
Barclays PLC Has $154,000 Stake in Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS)January 23 - ETF Daily News |
 |
Acumen Pharmaceuticals Announces Journal of Prevention of Alzheimer’s Disease Publication of the Company’s Phase 1 INTERCEPT-AD Study, Including Target Engagement, Dosing Regimen and Safety FindingsJanuary 8 - Yahoo |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 100,000 | 5M | -4.9M | -30M | -29M | -0.495 |
| Q2 '24 | 0 | 4.8M | -4.8M | -21M | -19M | -0.340 |
| Q1 '24 | 3M | 5.3M | -2.3M | -15M | -14M | -0.250 |
| Q4 '23 | 10M | 5.2M | 5M | -16M | -13M | -0.280 |
| Q3 '23 | 0 | 4.9M | -4.9M | -13M | -16M | -0.240 |
Insider Transactions View All
| Zuga Matt filed to sell 231,744 shares at $1.7. January 23 '25 |
| Siemers Eric filed to sell 170,298 shares at $1.6. January 23 '25 |
| Barton Russell filed to sell 136,117 shares at $1.6. January 23 '25 |
| Meisner Derek M filed to sell 161,127 shares at $1.6. January 23 '25 |
| Zuga Matt filed to sell 260,646 shares at $1.6. January 23 '25 |
Similar companies
Read more about Acumen Pharmaceuticals (ABOS) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, google trends, 4chan mentions, facebook engagement, facebook followers, instagram followers, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, news mentions, customer reviews & linkedin employees.
What is the Market Cap of Acumen Pharmaceuticals?
The Market Cap of Acumen Pharmaceuticals is $94M.
What is the current stock price of Acumen Pharmaceuticals?
Currently, the price of one share of Acumen Pharmaceuticals stock is $1.50.
How can I analyze the ABOS stock price chart for investment decisions?
The ABOS stock price chart above provides a comprehensive visual representation of Acumen Pharmaceuticals' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Acumen Pharmaceuticals shares. Our platform offers an up-to-date ABOS stock price chart, along with technical data analysis and alternative data insights.
Does ABOS offer dividends to its shareholders?
As of our latest update, Acumen Pharmaceuticals (ABOS) does not offer dividends to its shareholders. Investors interested in Acumen Pharmaceuticals should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Acumen Pharmaceuticals?
Some of the similar stocks of Acumen Pharmaceuticals are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.